Micro-dosing is the process of dispensing a precise amount of drug substance into a capsule (or other container, e.g. vial or bottle), for use in early phase human studies (phase I safety evaluations).
Micro-dosing for PIC evaluations is a key component of our early stage product development offering aimed at accelerated feasibility studies and first-in-human (FIH). By combining Xcelience’s market-leading experience in micro-dosing and Capsugel’s Xcelodose® Precision Powder Micro-Dosing Systems, we provide premier PIC evaluations and services for preclinical studies in support of client projects. PIC programs are generally completed 45% faster than traditional formulation development approaches using excipients, resulting in time savings of 13-17 weeks. Our micro-dosing service is complemented by a full range of clinical supply services including primary and secondary packaging, labeling, kitting, distribution and overall clinical supply management.
A summary of PIC program benefits using Xcelodose Systems follows:
Capsugel offers PIC services using Xcelodose Systems in North America (Xcelience – Tampa, FL) and Europe (Ploermel, FR). Both sites have integrated product development and manufacturing, and multiple Xcelodose units to support both pre-clinical assessments and clinical PIC manufacture. A full range of preformulation, analytical and formulation development services support phase I-IV studies and commercialization.